TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05384626: A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Sponsor: Nuvalent Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 840 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT05384626 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05384626 Rescue Dossier →